Search

Abbie C Celniker

from Los Angeles, CA
Age ~66
Get Report
Also known as:
Abbie C Celnicker, Abbie C Drain, Abbie C Mandehr, Abbie C Celmiker, Abby Celniker, Abbie R, Abby Celnicker
Related to:
Kelsey A Drain, 30
Connected to:
George W Celniker, 66Angelo J Celona, 64Doreen Celona, 64Karen M Celona, 54Dominick T Celone, 95Matthew T Celone, 49Thomas S Celone, 85Michelle C Celones, 53Mark T Celoni, 59Emanez D Celony, 57

Abbie Celniker Phones & Addresses

  • Los Angeles, CA
  • San Francisco, CA
  • Newbury, NH
  • 560 Chestnut St, Waban, MA 02468 (617) 332-0067 (617) 969-7030
  • Truckee, CA
  • Boston, MA
  • San Mateo, CA
  • Andover, MA
  • 560 Chestnut St, Waban, MA 02468 (617) 791-8255

Work

Company: Eleven biotherapeutics Sep 2011 Address: Cambridge, MA Position: Ceo

Education

Degree: PhD School / High School: University of Arizona, College of Medicine 1981 to 1986 Specialities: Molecular Biology

Skills

Life Sciences • Pharmaceutical Industry • Biopharmaceuticals • Clinical Development • Biotechnology • Biologics • Strategy • Protein Chemistry • Drug Discovery • Technology Transfer • Immunology • Venture Capital • Biochemistry • Clinical Research • Oncology • Cell Biology • Inflammation • Glp • Antibodies • Lifesciences • Science • Assay Development • Pharmacology • Translational Medicine • Bioanalysis • Drug Development • Molecular Biology • Commercialization • Managed Care • Cell • Cro • Fda • Genomics • Team Leadership • Executive Development • Infectious Diseases • Cancer • R&D • Cell Culture • Gmp • Clinical Trials • Pcr • Stem Cell Research

Emails

a***[email protected]

Industries

Biotechnology

Resumes

Resumes

Abbie Celniker Photo 1

Partner

View page
Location:
560 Chestnut St, Waban, MA 02468
Industry:
Biotechnology
Work:
Eleven Biotherapeutics - Cambridge, MA since Sep 2011
CEO
Alexion Pharmaceuticals Feb 2011 - Oct 2011
SVP, Translational Medicine
Taligen Therapeutics Inc. 2006 - Feb 2011
CEO
Novartis 2006 - 2008
Global Head of Biologics
Millennium Pharmaceuticals, Inc. 2000 - 2006
SVP, Pharmacuetical Sciences and Strategy and Operations
Education:
University of Arizona, College of Medicine 1981 - 1986
PhD, Molecular Biology University of California, San Diego 1976 - 1980
Bachelor of Sciences, Biology
Skills:
Life Sciences
Pharmaceutical Industry
Biopharmaceuticals
Clinical Development
Biotechnology
Biologics
Strategy
Protein Chemistry
Drug Discovery
Technology Transfer
Immunology
Venture Capital
Biochemistry
Clinical Research
Oncology
Cell Biology
Inflammation
Glp
Antibodies
Lifesciences
Science
Assay Development
Pharmacology
Translational Medicine
Bioanalysis
Drug Development
Molecular Biology
Commercialization
Managed Care
Cell
Cro
Fda
Genomics
Team Leadership
Executive Development
Infectious Diseases
Cancer
R&D
Cell Culture
Gmp
Clinical Trials
Pcr
Stem Cell Research

Business Records

Name / Title
Company / Classification
Phones & Addresses
Abbie Celniker
Director
MASSACHUSETTS BIOTECHNOLOGY EDUCATION FOUNDATION, INC
300 Technology Sq 8 Floor, Cambridge, MA 02139
215 1 St SUITE 400, Cambridge, MA 02142
Abbie Celniker
Manager
Bay State Financial Services
Insurance Agent/Broker Security Broker/Dealer Investment Advisory Service
1 Exeter Plz, Boston, MA 02116
200 Clarendon St, Boston, MA 02116
(617) 585-4500
Abbie Celniker
Chief Executive Officer
ALEXION CAMBRIDGE CORPORATION
Medical Laboratory
245 1 St SUITE 1830, Cambridge, MA 02142
(617) 299-3200

Publications

Us Patents

Humanized Immunoglobulin Reactive With B7 Therewith

View page
US Patent:
6913747, Jul 5, 2005
Filed:
Jun 24, 1999
Appl. No.:
09/339596
Inventors:
Man Sung Co - Cupertino CA, US
Maximiliano Vasquez - Palo Alto CA, US
Beatriz Carreno - Acton MA, US
Abbie Cheryl Celniker - Newton MA, US
Mary Collins - Natick MA, US
Samuel Goldman - Acton MA, US
Gary S. Gray - Brookline MA, US
Andrea Knight - Hampton NH, US
Denise O'Hara - Reading MA, US
Bonita Rup - Reading MA, US
Geertruida M. Veldman - Sudbury MA, US
International Classification:
A61K039/395
C07K016/28
C12N015/13
C12N015/63
US Classification:
4241531, 4241301, 4241331, 4241411, 4241431, 4241441, 4241731, 435 696, 435325, 435326, 435328, 435332, 435343, 4353431, 435346, 4352523, 4353201, 435455, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887, 53038873, 536 231, 536 235, 536 2353
Abstract:
The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Humanized Immunoglobulin Reactive With B7-2 And Methods Of Treatment Therewith

View page
US Patent:
6972125, Dec 6, 2005
Filed:
Feb 12, 1999
Appl. No.:
09/249011
Inventors:
Man Sung Co - Cupertino CA, US
Maximiliano Vasquez - Palo Alto CA, US
Beatriz Carreno - Acton MA, US
Abbie Cheryl Celniker - Newton MA, US
Mary Collins - Natick MA, US
Samuel Goldman - Acton MA, US
Gary S. Gray - Brookline MA, US
Andrea Knight - Hampton NH, US
Denise O'Hara - Reading MA, US
Bonita Rup - Reading MA, US
Geertruida M. Veldman - Sudbury MA, US
Assignee:
Genetics Institute, LLC - Cambridge MA
International Classification:
A61K039/395
C07K016/28
C12N015/13
US Classification:
4241531, 4241301, 4241331, 4241411, 4241431, 4241441, 4241731, 435 696, 4352523, 4353201, 435326, 435328, 435332, 435334, 435343, 4353431, 435346, 435440, 435455, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887, 53038873, 536 231, 536 234, 536 235, 536 2353
Abstract:
The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Method Of Transplanting Cells By Contacting Donor Cells With B7-1-And B7-2-Specific Immunoglobulins

View page
US Patent:
6984383, Jan 10, 2006
Filed:
Jul 27, 2000
Appl. No.:
09/626731
Inventors:
Man Sung Co - Cupertino CA, US
Maximiliano Vasquez - Palo Alto CA, US
Beatriz Carreno - Acton MA, US
Abbie Cheryl Celniker - Newton MA, US
Mary Collins - Natick MA, US
Samuel Goldman - Acton MA, US
Gary S. Gray - Brookline MA, US
Andrea Knight - Hampton NH, US
Denise O'Hara - Reading MA, US
Bonita Rup - Reading MA, US
Geertruida M. Veldman - Sudbury MA, US
Assignee:
Genetics Institute, LLC - Cambridge MA
International Classification:
A61K 39/395
A61K 35/26
A61K 35/28
C07K 16/28
US Classification:
4241531, 4241301, 4241331, 4241401, 4241411, 4241431, 4241441, 4241731, 424 937, 424 9371, 424577, 424578, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887, 53038873
Abstract:
The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Methods For Modulation Of Immune Responses Using Humanized Immunoglobulins Reactive With B7-1 Molecules

View page
US Patent:
7531175, May 12, 2009
Filed:
Nov 12, 2004
Appl. No.:
10/986089
Inventors:
Man Sung Co - Cupertino CA, US
Maximiliano Vasquez - Palo Alto CA, US
Beatriz Carreno - Acton MA, US
Abbie Cheryl Celniker - Newton MA, US
Mary Collins - Natick MA, US
Samuel Goldman - Acton MA, US
Gary S. Gray - Brookline MA, US
Andrea Knight - Hampton NH, US
Denise O'Hara - Reading MA, US
Bonita Rup - Reading MA, US
Geertruida M. Veldman - Sudbury MA, US
Assignee:
Genetics Institute LLC - Madison NJ
International Classification:
A61K 39/395
C07K 16/28
US Classification:
4241531, 4241301, 4241331, 4241401, 4241411, 4241431, 4241731, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887, 53038873
Abstract:
The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Methods Of Treatment Of Autoimmune Diseases Using Humanized Immunoglobulin Reactive With B7-2

View page
US Patent:
7666421, Feb 23, 2010
Filed:
Dec 5, 2005
Appl. No.:
11/294680
Inventors:
Man Sung Co - Cupertino CA, US
Maximiliano Vasquez - Palo Alto CA, US
Beatriz Carreno - Acton MA, US
Abbie Cheryl Celniker - Newton MA, US
Mary Collins - Natick MA, US
Samuel Goldman - Acton MA, US
Gary S. Gray - Brookline MA, US
Andrea Knight - Hampton NH, US
Denise O'Hara - Reading MA, US
Bonita Rup - Reading MA, US
Geertruida M. Veldman - Sudbury MA, US
Assignee:
Genetics Institute, LLC - Cambridge MA
International Classification:
A61K 39/395
C07K 16/28
US Classification:
4241531, 4241301, 4241331, 4241401, 4241411, 4241431, 4241731, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887, 53038873
Abstract:
The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Humanized Immunoglobulin Reactive With B7 Molecules And Methods Of Treatment Therewith

View page
US Patent:
20080050368, Feb 28, 2008
Filed:
Sep 26, 2006
Appl. No.:
11/527160
Inventors:
Abbie Cheryl Celniker - Newton MA, US
Gary S. Gray - Brookline MA, US
Assignee:
Genetics Institute, LLC - Cambridge MA
International Classification:
A61K 31/44
A61K 39/00
A61K 39/395
A61P 43/00
US Classification:
4241331, 4241301, 514336
Abstract:
The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Humanized Immunoglobulin Reactive With B7-2 And Methods Of Treatment Therewith

View page
US Patent:
6827934, Dec 7, 2004
Filed:
Jul 27, 2000
Appl. No.:
09/627896
Inventors:
Man Sung Co - Cupertino CA
Maximiliano Vasquez - Palo Alto CA
Beatriz Carreno - Acton MA
Abbie Cheryl Celniker - Newton MA
Mary Collins - Natick MA
Samuel Goldman - Acton MA
Andrea Knight - Hampton NH
Denise OHara - Reading MA
Bonita Rup - Reading MA
Geertruida M. Veldman - Sudbury MA
Gary S. Gray - Brookline MA
Assignee:
Genetics Institute, LLC - Cambridge MA
International Classification:
A61K 39395
US Classification:
4241531, 4241301, 4241331, 4241411, 4241431, 4241441, 4241731, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887, 53038873
Abstract:
The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
Control profile
Abbie C Celniker from Los Angeles, CA, age ~66 Get Report